Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients
Abstract background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group rece...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academia Brasileira de Ciências
2022-09-01
|
| Series: | Anais da Academia Brasileira de Ciências |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652022000600701&tlng=en |
| _version_ | 1811344106338648064 |
|---|---|
| author | MEENU BAJPAI ASHISH MAHESHWARI SURESH KUMAR KARAN CHHABRA PRATIBHA KALE ASHAD NARAYANAN AMITA GUPTA EKTA GUPTA NIRUPAMA TREHANPATI RESHU AGARWAL KAMINI GUPTA ANKIT BHARDWAJ MOJAHIDUL ISLAM RAVINDER SINGH PUSHPA YADAV GURESH KUMAR SHIV K. SARIN |
| author_facet | MEENU BAJPAI ASHISH MAHESHWARI SURESH KUMAR KARAN CHHABRA PRATIBHA KALE ASHAD NARAYANAN AMITA GUPTA EKTA GUPTA NIRUPAMA TREHANPATI RESHU AGARWAL KAMINI GUPTA ANKIT BHARDWAJ MOJAHIDUL ISLAM RAVINDER SINGH PUSHPA YADAV GURESH KUMAR SHIV K. SARIN |
| author_sort | MEENU BAJPAI |
| collection | DOAJ |
| description | Abstract background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease. Results: The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups. |
| first_indexed | 2024-04-13T19:41:53Z |
| format | Article |
| id | doaj.art-32d39f9771e94ec18ccce02db649aeef |
| institution | Directory Open Access Journal |
| issn | 1678-2690 |
| language | English |
| last_indexed | 2024-04-13T19:41:53Z |
| publishDate | 2022-09-01 |
| publisher | Academia Brasileira de Ciências |
| record_format | Article |
| series | Anais da Academia Brasileira de Ciências |
| spelling | doaj.art-32d39f9771e94ec18ccce02db649aeef2022-12-22T02:32:51ZengAcademia Brasileira de CiênciasAnais da Academia Brasileira de Ciências1678-26902022-09-0194410.1590/0001-3765202220210202Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patientsMEENU BAJPAIhttps://orcid.org/0000-0002-4872-7845ASHISH MAHESHWARIhttps://orcid.org/0000-0002-0716-939XSURESH KUMARhttps://orcid.org/0000-0001-8766-6937KARAN CHHABRAhttps://orcid.org/0000-0001-5710-7026PRATIBHA KALEhttps://orcid.org/0000-0002-5172-0193ASHAD NARAYANANhttps://orcid.org/0000-0003-2531-1094AMITA GUPTAhttps://orcid.org/0000-0003-1369-9853EKTA GUPTAhttps://orcid.org/0000-0002-5237-216XNIRUPAMA TREHANPATIhttps://orcid.org/0000-0002-6109-0033RESHU AGARWALhttps://orcid.org/0000-0002-9207-3607KAMINI GUPTAhttps://orcid.org/0000-0003-2091-1007ANKIT BHARDWAJhttps://orcid.org/0000-0002-5380-2782MOJAHIDUL ISLAMhttps://orcid.org/0000-0001-7219-9686RAVINDER SINGHhttps://orcid.org/0000-0003-0603-8328PUSHPA YADAVhttps://orcid.org/0000-0001-5285-7936GURESH KUMARhttps://orcid.org/0000-0002-8864-3849SHIV K. SARINhttps://orcid.org/0000-0002-0544-5610Abstract background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease. Results: The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652022000600701&tlng=enCOVID-19convalescent plasmadonor plasmapheresisARDSimmunoglobulinsantibodies |
| spellingShingle | MEENU BAJPAI ASHISH MAHESHWARI SURESH KUMAR KARAN CHHABRA PRATIBHA KALE ASHAD NARAYANAN AMITA GUPTA EKTA GUPTA NIRUPAMA TREHANPATI RESHU AGARWAL KAMINI GUPTA ANKIT BHARDWAJ MOJAHIDUL ISLAM RAVINDER SINGH PUSHPA YADAV GURESH KUMAR SHIV K. SARIN Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients Anais da Academia Brasileira de Ciências COVID-19 convalescent plasma donor plasmapheresis ARDS immunoglobulins antibodies |
| title | Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients |
| title_full | Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients |
| title_fullStr | Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients |
| title_full_unstemmed | Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients |
| title_short | Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients |
| title_sort | comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid 19 patients |
| topic | COVID-19 convalescent plasma donor plasmapheresis ARDS immunoglobulins antibodies |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652022000600701&tlng=en |
| work_keys_str_mv | AT meenubajpai comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT ashishmaheshwari comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT sureshkumar comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT karanchhabra comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT pratibhakale comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT ashadnarayanan comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT amitagupta comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT ektagupta comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT nirupamatrehanpati comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT reshuagarwal comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT kaminigupta comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT ankitbhardwaj comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT mojahidulislam comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT ravindersingh comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT pushpayadav comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT gureshkumar comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients AT shivksarin comparisonofsafetyandefficacyofconvalescentplasmawithfreshfrozenplasmainseverecovid19patients |